Australia could see steady biotech growth due to R&D tax incentives, a former investment banker as the country's new prime minster, and the launch earlier this year of Brandon Capital Partners' A$200 million Medical Research Commercialization Fund.
Due in part to the increasing geriatric population and the increasing number of emergency cases, the inhalation anesthesia market is expected to grow significantly for the foreseeable future.
NantKwest Inc. experienced the highest ever IPO valuation for a biotech company with no approved drugs with a valuation on the first day of public trading of $2.6B. Despite the risks of drug development, investments into mutual funds and exchange-traded funds with the word 'biotechnology' in their name reached $6.2B in the first half of 2015, compared to the $3.5B invested in all of 2014.
The U.S. general anesthesia drug market is expected to grow with a CAGR of 3.8% from 2015 to 2020, resulting in a market size of $2.0 billion up from $1.6 billion today.
Novo Holdings’ recent launch of a $165 million venture fund focused on tackling “superbugs†resistant to modern antibiotics demonstrates the paradigm shift occurring in Big Pharma. Novo’s Repair Impact Fund — Repair stands for Replenishing and Enabling the Pipeline for Anti-Infective Resistance — will invest $20 million to $40 million in start-ups and early stage companies in the United States and Europe that have new approaches to combat bacteria that pose the greatest threat to human health.